Journals / Journal of Clinical Research in Pediatric Endocrinology / 2017 / Cilt: 9 - Sayı: 3

Clinical and Genetic Findings of Turkish Hypophosphatasia Cases

Pages
229–236
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Laboratory findings were normal in these cases.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Hypophosphatasia (HPP) is a rare, commonly unrecognized hereditary mineralization defect with a dramatically poor prognosis in severe cases.
📊
Key Findings & Data:This study is the first to examine the detailed clinical and laboratory characteristics of patients with HPP and healthy carriers in Turkey.Methods: The study data were obtained retrospectively from the files of 10 healthy carriers and of 16 cases with HPP (12 children and 4 adults) who were followed in our center from 2012 to 2016.Results: The annual incidence of perinatal lethal hypophosphatasia (PLH) was estimated to be approximately 1 case per 435,517 live births,, which is the first report from Turkey.
💡
Conclusion & Impact:Laboratory findings were normal in these cases.
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Hypophosphatasia (HPP) is a rare, commonly unrecognized hereditary mineralization defect with a dramatically poor prognosis in severe cases. This study is the first to examine the detailed clinical and laboratory characteristics of patients with HPP and healthy carriers in Turkey.Methods: The study data were obtained retrospectively from the files of 10 healthy carriers and of 16 cases with HPP (12 children and 4 adults) who were followed in our center from 2012 to 2016.Results: The annual incidence of perinatal lethal hypophosphatasia (PLH) was estimated to be approximately 1 case per 435,517 live births,, which is the first report from Turkey. The clinical courses of the cases differed depending on the type of HPP. All of the seven cases (58.3% of all cases) with perinatal lethal form of HPP died. A need for respiratory support (p=0.001), a history of pyridoxine-dependent seizures (p=0.001), a low chest circumference measurement (p=0.017), younger age at diagnosis (p=0.029), a small head circumference at the time of presentation (p=0.042), a low arm span to height ratio (p=0.048), and a low serum alkaline phosphatase (ALP) level (p=0.042) seemed to be predicting factors for mortality. The mean height standard deviation score of the patients and those of the healthy carriers did not differ significantly (p=0.173). Different mutations were detected in nine of 14 cases (64.2%) in whom an ALPL gene mutation analysis could be performed, and five of these cases (35.7%) had novel mutations. The most common mutations were c746G>T (five alleles), c346G>A (three alleles), and c.140C>T (three alleles). In addition, the most frequently observed genotype in Turkish HPP cases was autosomal-dominant c.346G>A (p.A116T) mutations which were detected in three cases in two different families.Conclusion: Because of the respiratory problems, especially the lung hypoplasia, the clinical course is poor in cases with the perinatal lethal form of HPP. Some minor abnormalities such as mild short stature and osteopenia could be observed in asymptomatic heterozygote carriers. Laboratory findings were normal in these cases.

🔖

Cite This Article

SAĞLAM, H., ERDÖL, Ş., DORUM, S. (2017). Clinical and Genetic Findings of Turkish Hypophosphatasia Cases. Journal of Clinical Research in Pediatric Endocrinology, Cilt: 9 - Sayı: 3, 229–236. https://ajindex.com/articles/205080

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Rathbun JC. Hypophosphatasia; a new developmental anomaly. Am J Dis Child 1948;75:822-831
  2. Whyte MP. Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment. Nat Rev Endocrinol 2016;12:233-246. Epub 2016 Feb 19 3. Oda K, Kinjoh NN, Sohda M, Komaru K, Amizuka N. Tissuenonspecific alkaline phosphatase and hypophosphatasia. Clin Calcium 2014;24:233-239
  3. Baumgartner-Sigl S, Haberlandt E, Mumm S, Scholl-Bürgi S, Sergi C, Ryan L, Ericson KL, Whyte MP, Högler W. Pyridoxine-responsive seizures as the first symptom of infantile hypophosphatasia caused by two novel missense mutations (c.677T>C, p.M226T; c.1112C>T, p.T371I) of the tissue-nonspecific alkaline phosphatase gene. Bone 2007;40:1655-1661. Epub 2007 Feb 14 5. Whyte MP, Wenkert D, Zhang F. Hypophosphatasia: natural history study of 101 affected children followed at one research center. Bone 2016;93:125-138. Epub 2016 Aug 27 6. Mornet E, Yvard A, Taillandier A, Fauvert D, Simon-Bouy B. A molecular-based estimation of the prevalence of hypophosphatasia in the European population. Ann Hum Genet 2011;75:439-445. Epub 2011 Mar 24 7. Ozono K. Enzyme replacement therapy for hypophosphatasia. Clin Calcium 2014;24:257-263
  4. Diaku-Akinwumi IN, Akodu SO, Njokanma OF. Upper body segment to lower body segment and arm span to height ratios among children with sickle cell anaemia in Lagos. Niger J Paed 2013;40:222-226
  5. Bianchi ML. Hypophosphatasia: an overview of the disease and its treatment. Osteoporos Int 2015;26:2743-2757. Epub 2015 Aug 6 10. Mornet E, Taillandier A, Peyramaure S, Kaper F, Muller F, Brenner R, Bussière P, Freisinger P, Godard J, Le Merrer M, Oury JF, Plauchu H, Puddu R, Rival JM, Superti-Furga A, Touraine RL, Serre JL, Simon-Bouy B. Identification of fifteen novel mutations in the tissue-nonspecific alkaline phosphatase (TNSALP) gene in European patients with severe hypophosphatasia. Eur J Hum Genet 1998;6:308-314. 11. "Birth Statistics" Turkish Statistical Institution. 15 April 2016. Web. 09 May 2016,
  6. Taketani T, Onigata K, Kobayashi H, Mushimoto Y, Fukuda S, Yamaguchi S. Clinical and genetic aspects of hypophosphatasia in Japanese patients. Arch Dis Child 2014;99:211-215. Epub 2013 Nov 25 13. Fraser D. Hypophosphatasia. Am J Med 1957;22:730-746
  7. Watanabe A, Karasugi T, Sawai H, Naing BT, Ikegawa S, Orimo H, Shimada T. Prevalence of c.1559delT in ALPL, a common mutation resulting in the perinatal (lethal